Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,334 result(s) found. Displaying page 1,678 of 2,217.
    «« First « Previous 1674  1675  1676  1677  1678  1679  1680  1681  1682  Next» Last»»
    EudraCT Number: 2020-003358-63 Sponsor Protocol Number: 2020033183. Start Date*: 2020-12-10
    Sponsor Name:Bispebjerg Hospital
    Full Title: OPTIMAL - Titration of treatment with biologics in severe asthma
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001734-34 Sponsor Protocol Number: CLNP023D12201 Start Date*: 2019-09-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatmen...
    Medical condition: Idiopathic Membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004544-38 Sponsor Protocol Number: C3601009 Start Date*: 2020-07-03
    Sponsor Name:Pfizer Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INF...
    Medical condition: SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021804 Infection bacterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2023-000824-12 Sponsor Protocol Number: B7981031 Start Date*: 2023-09-06
    Sponsor Name:Pfizer, Inc.
    Full Title: AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA
    Medical condition: Alopecia Areata
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000533-40 Sponsor Protocol Number: CIBI308A301 Start Date*: 2020-10-05
    Sponsor Name:Innovent Biologics (Suzhou) Co., Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectab...
    Medical condition: Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030187 Oesophageal squamous cell carcinoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058527 Oesophageal squamous cell carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001019-19 Sponsor Protocol Number: UX007 Start Date*: 2016-06-27
    Sponsor Name:LIEGE University Hospital
    Full Title: A pilot trial of triheptanoin for the preventive treatment of migraine
    Medical condition: Migraine
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006007-15 Sponsor Protocol Number: JAKAR Start Date*: 2022-09-01
    Sponsor Name:Leiden University Medical Center (LUMC)
    Full Title: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis
    Medical condition: patients with ACPA-positieve active RA
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002061-22 Sponsor Protocol Number: RC17_0061 Start Date*: 2017-09-12
    Sponsor Name:CHU de Nantes
    Full Title: A phase III randomized, blind, double dummy, multicenter study assessing the efficacy and safety of IV thrombolysis (alteplase) in patients with acute central retinal artery occlusion
    Medical condition: acute central retinal artery occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10043568 Thrombolysis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006611-68 Sponsor Protocol Number: shey01.2006 Start Date*: 2007-05-07
    Sponsor Name:academic hospital Maastricht
    Full Title: Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies
    Medical condition: patients suffering from heartfailure and inflammatory cardiomyopthies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004308-37 Sponsor Protocol Number: C19-28 Start Date*: 2021-01-20
    Sponsor Name:Institut National de la Santé et de la Recherche Médicale (INSERM)
    Full Title: Penetration of the innovative antibiotic gepotidacin into prostate and tonsillar tissue.
    Medical condition: Cohort A: Male patients with localized prostate cancer scheduled to undergo radical prostatectomy and patients with benign prostate hyperplasia scheduled to undergo simple prostatectomy Cohort B:...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005773-27 Sponsor Protocol Number: APHP190353 Start Date*: 2021-03-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
    Full Title: BARIcitinib Cognitive Emotional and Neural signaTuRE BARICENTRE
    Medical condition: Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005883-78 Sponsor Protocol Number: CHRD1520 Start Date*: 2021-02-05
    Sponsor Name:Hospital Center rené Dubos
    Full Title: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19
    Medical condition: Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    21.1 100000004855 10042839 Syndrome respiratory distress adult LLT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001453-31 Sponsor Protocol Number: CONMED3 Start Date*: Information not available in EudraCT
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study
    Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us...
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029205 - Nervous system disorders 10013509 Disturbances in consciousness NEC HLT
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003564-24 Sponsor Protocol Number: JAB-3312-1003 Start Date*: 2023-05-05
    Sponsor Name:Jacobio Pharmaceuticals Co., Ltd.
    Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000620-18 Sponsor Protocol Number: RC20_0082 Start Date*: 2021-02-19
    Sponsor Name:Nantes University Hospital
    Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the...
    Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005827-35 Sponsor Protocol Number: RC31/20/0441 Start Date*: 2021-03-25
    Sponsor Name:University Hospital of Toulouse
    Full Title: SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium
    Medical condition: delirium
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001335-28 Sponsor Protocol Number: IFX-1-P2.9 Start Date*: 2020-03-29
    Sponsor Name:InflaRx GmbH
    Full Title: A pragmatic adaptive randomized controlled Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO"
    Medical condition: Severe pneumonia in context of COVID-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004037-17 Sponsor Protocol Number: 19_RIPH1_07 Start Date*: 2021-07-28
    Sponsor Name:Centre Hospitalier Universitaire de Martinique
    Full Title: Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overse...
    Medical condition: Mild Leptospirosis : defined as Leptospirosis without the following severity criteria : a. Hemodynamic failure* with onset of septic shock b. Hematologic failure* with hemoglobin requiring red blo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024238 Leptospirosis PT
    20.0 10021881 - Infections and infestations 10024241 Leptospirosis, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000987-53 Sponsor Protocol Number: INCB18424-308 Start Date*: 2021-04-18
    Sponsor Name:Incyte Corporation
    Full Title: A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1674  1675  1676  1677  1678  1679  1680  1681  1682  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:29:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA